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blind, placebo controlled, clinical trial to develop a model to
assess the utility and costs associated with eszopiclone treatment
of primary insomnia. Treatment of insomnia was evaluated using
the Insomnia Severity Index, which categorizes insomnia as not
clinically signiﬁcant, subtheshold, moderate, and severe. Quality
of life data were collected in the trial using the SF-36. From these
responses, preference-based utility scores were derived using an
algorithm published by Franks et al. (2004). Insomnia costs were
based on published data, and included the additional health care
costs of patients with insomnia versus patients with no insomnia,
the additional absenteeism costs due to insomnia, and the “pre-
senteeism” (lost productivity while at work) costs as measured by
the Work Limitations Questionnaire. Eszopiclone cost was based
on the average wholesale price. Changes in the average quality-
adjusted life years (QALYs) and costs from baseline to 6 months
for patients in both treatment groups were calculated and 95%
credible intervals generated by a bootstrapping algorithm. All
costs are presented in 2006 US dollars. RESULTS: The average
6-month changes in QALYs were 0.010514 and -0.003201 for
eszopiclone and placebo groups, respectively, for a mean net gain
of 0.013714 (95% CI: 0.0053525, 0.021885). The average
6-month costs per patient including indirect productivity were
$490 and $421, respectively, indicating a net cost of $69 (-$436,
$325). Incremental costs per QALY gained associated with
eszopiclone were $5,003 (-$12,603, $41,376) per patient over
the 6-month time period when absenteeism and presenteeism
costs were included and $33,110 ($20,679, $83,846) when
excluded. CONCLUSION: Based on this model, eszopiclone
treatment of insomnia was cost effective considering lost produc-
tivity, and remained cost effective even when excluding produc-
tivity costs.
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OBJECTIVES: The purpose of this study is to evaluate the cost-
effectiveness of an ambulatory care strategy for patients with TIA
by using a neurosonological study at emergency department
versus the standard protocol based on inpatient care
METHODS: This is a partially stochastic cost-effectiveness
analysis where effectiveness data were collected by means of a
follow-up cohort study. Period of study cover from 1st January of
2002 to 30th June 2005, when 338 patients with TIA were
treated in the Neurology department of the University Hospital
Virgen de las Nieves (Granada, Spain). Effectiveness variables
were survival, disability degree, relapse, sequels and cardiac
event after TIA. Cost analysis adopts the hospital perspective,
including overheads and direct costs. Economic data were
obtained from hospital’s analytical accounting. The cost-
effectiveness analysis was carried out considering the 5 effective-
ness variables mentioned. A one-way sensitivity analysis was
performed. RESULTS: Costs of ambulatory and hospitalization
care were 428.08€ and 2,297.87€ respectively. Considering sur-
vival and relapse, hospitalization treatment is more effective than
ambulatory, but regarding disability, sequels and cardiac events
ambulatory outcomes were more favourable in ambulatory pro-
tocol. None of these differences was statistically signiﬁcant. Cost-
effectiveness analyses based on disability, sequels and cardiac
events show strongly dominance of ambulatory protocol. Cost-
effectiveness analyses on survival and relapse report an incremen-
tal cost-effectiveness ratio (ICER) of 93,489€ and 46,745€
respectively. Sensitivity analysis conﬁrms the robustness of pre-
vious results. CONCLUSION: The effectiveness equivalence of
both ambulatory and hospitalisation treatments and the much
fewer costs of ambulatory care, support the recommendation of
a spread of the ambulatory treatment instead of the hospital one.
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OBJECTIVES: Choosing an antiepileptic drug (AED) can be a
complex decision for clinicians. This study aims to estimate the
cost-effectiveness of levetiracetam adjunctive therapy compared
to topiramate adjunctive therapy for the treatment of refractory
primary generalised tonic-clonic seizures (PGTCS) in the Scottish
health care setting. METHODS: A Markov model was developed
to assess the clinical and economic outcomes of levetiracetam
adjunctive therapy compared to topiramate adjunctive therapy in
patients with refractory PGTCS. The model simulates the treat-
ment pathway of a hypothetical cohort of 1000 patients over one
year. Efﬁcacy data were drawn from ﬁve randomized clinical
trials. Data for each three-month cycle on risk of withdrawal,
adverse events and mortality were obtained from the published
literature. Resource use data and costs were obtained from pub-
lished data and were based on the Scottish NHS perspective.
Only direct costs relating to the management and treatment of
refractory PGTCS and adverse events were considered. Health
beneﬁts were assessed in terms of seizure-free cycles and quality-
adjusted life years (QALYs). Deterministic and probabilistic sen-
sitivity analyses explored the robustness of the results. RESULTS:
In the base case scenario, the model predicts approximately 3800
seizure-free cycles for topiramate versus 4000 for levetiracetam.
QALYs gained are slightly higher for levetiracetam than topira-
mate (990 vs. 980). Total costs relating to topiramate and leve-
tiracetam are similar (1,555,000 and1,500,000 respectively).
Consequently, levetiracetam adjunctive therapy dominates topi-
ramate adjunctive therapy. Varying AED costs did not have a
major impact on the results of the cost-effectiveness analysis.
Using a threshold of 30,000 per QALY, levetiracetam is cost-
effective compared to topiramate in 85% of refractory PGTCS
patients. CONCLUSION: Levetiracetam adjunctive therapy
appears to be cost-effective for the treatment of refractory
patients with PGTCS. Levetiracetam adjunctive therapy domi-
nates topiramate adjunctive therapy, its acquisition cost being
offset by reduced seizure management costs and a better toler-
ability proﬁle.
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OBJECTIVES: Lennox-Gastaut syndrome (LGS) is a severe form
of childhood epilepsy. The cost-effectiveness of ruﬁnamide versus
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